Antiplasmodial Activity of Artemether-Lumefantrine-Tinidazole on Plasmodium Berghei Infected Mice


P. berghei

How to Cite

Georgewill U, Harold M, Elias A. Antiplasmodial Activity of Artemether-Lumefantrine-Tinidazole on Plasmodium Berghei Infected Mice. Health Sci. [Internet]. 2020 Oct. 22 [cited 2022 May 16];. Available from:


Introducion: The impact of malaria scourge has been characterized by daunting challenges including antimalarial drug resistance. This necessitates the search for newer antimalaria drugs using approaches including drug repurposing. This study assessed whether Tinidazole (T) can be repurposed as antimalaria in combination with artemether/lumefantrine (A/L) in Plasmodium berghei infected mice. Materials and Methods: Plasmodium berghei infected mice were grouped and orally treated with A/L (2.3/13.7mg/kg), T (28.6 mg/kg), and A/L/T daily in curative, suppressive and prophylactic studies. The negative control (NC) and positive control (MC) were orally treated with 0.9% normal saline (0.2mL) and chloroquine (CQ) (10mg/kg) daily for 4 days, respectively. After drug administration, blood samples were collected and evaluated for parasitemia level, lipid, and hematological parameters. Results: Significant decreases in parasitemia levels in the curative, suppressive, and prophylactic groups were observed in mice treated with T (28.6 mg/kg) (p<0.05), A/L (2.3/13.7 mg/kg) (p<0.01), and A/L/T (p<0.001) when compared to negative control. Mean survival times were significantly increased at T (28.6 mg/kg) (p<0.05), A/L (2.3/13.7mg/kg) (p<0.01) and A/L/T (p<0.001) when compared to negative control. Red blood cells, hemoglobin, packed cell volume, high-density lipoprotein, cholesterol levels were significantly (p<0.001) increased whereas white blood cells, total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels were significantly decreased at T (28.6 mg/kg) (p<0.05), A/L (2.3/13.7mg/kg) (p<0.01) and A/L/T (p<0.001) when compared to a negative control. The antiplasmodial effect of A/L/T differs significantly (p<0.05) when compared to positive control. Conclusion: This study recommends the repurposing of tinidazole in combination with artemether/lumefantrine for malaria treatment and further studies in humans.


Alexis N, Ma Z. Chibale K. Drug repositioning in the treatment of malaria and TB. Future Med Chem. 2011; 3(11), 1413–1426.

World Health Organization. The global burden of disease. 2004 update. 2008. [Cited 2022 Mar 22]. Available from:

World Health Organisation (WHO) world’s malaria report 2007.

World Health Organization. Global report on antimalarial drug efficacy and drug resistance: 2000–2010. 2010. [Cited 2022 Mar 22]. Available from:

Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J. Artemisinin resistance in plasmodium falciparum malaria. N Engl J Med. 2009; 361 (5): 455–467.

Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisininresistant Plasmodium falciparum malaria. Nature. 2014 Jan 2;505(7481):50-5.

Andrews KT, Fisher G, Skinner-Adams TS. Drug repurposing and human parasitic protozoan diseases. Int J Parasitol Drugs Drug Resist. 2014 Mar 24;4(2):95-111.

Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83.

Campas C. Drug repositioning summit: finding new routes to success. Drug News Perspect. 2009 Mar;22(2):126-8.

Sarma P. Tinidazole: a new drug in the treatment of vivax malaria. Curr Ther Res 1988, 43:3.

Deye G, Gettayacamin M, Pranee H, Im-erbsin R, Sattabongkot J, Rothstein Y, et al. Use of Rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. Am J Trop Med Hyg. 2012 Jun;86(6):931-5.

Macareo L, Lwin KM, Cheah PY, Yuentraku P, Miller RS, Nosten F. Triangular test design to evaluate tinidazole in the prevention of Plasmodium vivax relapse. Malar J. 2013 May 29;12:173.

Somsak V, Damkaew A, Onrak P. Antimalarial Activity of Kaempferol and Its Combination with Chloroquine in Plasmodium berghei Infection in Mice. J Pathog. 2018 Dec 2;2018:3912090.

Sirima SB, Ogutu B, Lusingu JPA, Mtoro A, Mrango Z, Ouedraogo A, et al. Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Lancet Infect Dis. 2016;16(10):1123-1133.

Pehrson f, Bengtsson E. Treatment of non-invasive amoebiasis—a comparison between tinidazole and metronidazole. Ann Tropical Medicine & Parasitology1984; 78:5,505-508.

Knight DJ, Peters W. The antimalarial activity of N-benzyloxydihydrotriazines. I. The activity of clociguanil (BRL 50216) against rodent malaria, and studies on its mode of action. Ann of Trop Med Par. 1980 Aug;74(4):393-404.

Ryley JF, PetersW. The antimalarial activity of some quinolone esters. Ann Trop Med Parasitol. 1970 Jun;64(2):209-22.

Peters W. Rational methods in the search for antimalarial drugs. Trans R Soc Trop Med Hyg. 1967; 61: 400-410.

Nwaka S, Hudson A. Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov. 2006 Nov; 5(11):941-55.

Nzila A. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J Antimicrob Chemother. 2006 Jun;57(6):1043-54.

Olanlokun JO, Babarinde CO, Olorunsogo OO. Toxicity of Anchomanes difformis, An Antimalarial Herb in Murine Models. Eur Jour Med Plants. 2017; 20(3): 1-13.

White NJ. Anaemia and malaria. Malar J. 2018 Oct 19;17(1):371.

Labaied M, Jayabalasingham B, Bano N, Cha SJ, Sandoval J, Guan G, et al. Plasmodium salvages cholesterol internalized by LDL and synthesized de novo in the liver. Cell Microbiol. 2011 Apr;13(4):569-86.

Njoku OU, Ononogbu IC, Nwachukwu DE. Plasma cholesterol, B-carotene and ascorbic acid changes in human malaria. J Commun Dis. 1995; 27(3):186–190. [Cited 2022 Mar 22]. Available from:,%20B-CAROTENE%20AND%20ASCORBIC%20ACID%20CHANGES%20IN%20HUM.pdf

Fielding PE, Fielding CJ. Dynamics of lipoprotein transport in the human circulatory system. New Compr Biochem. 2002; 36:527–552. [Cited 2022 Mar 22]. Available from:

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2020 Udeme Georgewill